You have free access to this content

Cancer

Cover image for Vol. 118 Issue 16

15 August 2012

Volume 118, Issue 16

Pages 3879–4095

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Review Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Exploring biomarkers in head and neck cancer (pages 3882–3892)

      Corey J. Langer

      Article first published online: 26 JAN 2012 | DOI: 10.1002/cncr.26718

      Biomarker research in squamous cell carcinoma of the head and neck (SCCHN) has produced recent advances; certain markers, such as ERCC1 and RRM1, may help refine the use of chemotherapy, and human papillomavirus status defines a distinct subtype of oropharyngeal disease with better prognosis. However, there are no prospectively validated markers for epidermal growth factor receptor-targeted therapies in SCCHN or for conventional cytotoxic agents.

      Corrected by:

      Erratum: Erratum: Exploring biomarkers in head and neck cancer

      Vol. 118, Issue 23, 6014, Article first published online: 8 MAY 2012

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy (pages 3893–3898)

      Shirin Sioshansi, Shahrzad Ehdaivand, Christina Cramer, Michele M. Lomme, Lori Lyn Price and David E. Wazer

      Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.27376

      This reexcision study shows that triple negative breast cancers have a statistically significant association with an increased risk of residual tumor after breast conservation surgery. This suggests the putative increase in the risk of local failure in triple negative patients may be related to increased residual tumor burden.

    2. You have free access to this content
      Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer (pages 3899–3910)

      Masahiro Sakakibara, Toshihiko Fujimori, Tetsutaro Miyoshi, Takeshi Nagashima, Hiroshi Fujimoto, Hiroshi Tiberu Suzuki, Yohsuke Ohki, Koya Fushimi, Jissei Yokomizo, Yukio Nakatani and Masaru Miyazaki

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26725

      The responsiveness of primary and metastatic lesions to chemotherapy and its prognostic significance are examined in aldehyde dehydrogenase 1 (ALDH1)-positive cells from patients with breast cancer. ALDH1-positive status may represent a surrogate marker as a new concept in patients with lymph node-positive breast cancer.

    3. Gastrointestinal Disease
      You have free access to this content
      Beta blocker use and colorectal cancer risk : Population-based case-control study (pages 3911–3919)

      Lina Jansen, Janina Below, Jenny Chang-Claude, Hermann Brenner and Michael Hoffmeister

      Article first published online: 14 MAY 2012 | DOI: 10.1002/cncr.26727

      Results of this study do not support the hypothesis that beta blocker use is associated with decreased risk of colorectal cancer. In contrast, a positive association of long-term beta blocker use and risk of stage IV colorectal cancer is found, which should be investigated in future studies.

    4. Genitourinary Disease
      You have free access to this content
      Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder (pages 3920–3927)

      Christopher Blick, Peter Hall, Thinn Pwint, Faisal Al-Terkait, Jeremy Crew, Thomas Powles, Valentine Macaulay, Nicholas Munro, David Douglas, Neviana Kilbey, Andrew Protheroe and John D. Chester

      Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.26675

      Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) has many of the characteristics of an ideal neoadjuvant chemotherapy regimen: it minimizes delays to definitive treatment; it is safe, well-tolerated, and effective, resulting in excellent pathological and radiological response rates; and it has good long-term outcomes. It is an appropriate comparator for future randomized trials of neoadjvuant chemotherapy for muscle-invasive bladder cancer.

    5. Head and Neck Disease
      You have free access to this content
      Prognostic factors in mucoepidermoid carcinoma of the salivary glands (pages 3928–3936)

      Catherine H. McHugh, Dianna B. Roberts, Adel K. El-Naggar, Ehab Y. Hanna, Adam S. Garden, Merrill S. Kies, Randal S. Weber and Michael E. Kupferman

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26697

      High histological grade, advanced stage, perineural invasion, positive surgical margins, and submandibular location all portend poor outcomes of mucoepidermoid carcinoma. Further advances in therapy are needed to improve outcomes for patients with high-grade histology and advanced-stage disease.

    6. You have free access to this content
      Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma (pages 3937–3944)

      Benjamin Lok, Sabrina Khan, Robert Mutter, Jeffrey Liu, Ryan Fields, Melissa Pulitzer, Weiji Shi, Zhigang Zhang, Dennis Kraus, David Pfister, Klaus J. Busam, Isaac Brownell and Nancy Lee

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26738

      Adjuvant radiotherapy may benefit patients with Merkel cell carcinoma, which is a rare aggressive neuroendocrine tumor of the skin that is prone to high rates of locoregional failure and systemic progression. The authors report a site-specific series of head and neck Merkel cell carcinoma patients who received radiotherapy and observe that radiation is well tolerated and the rate of locoregional recurrence is low.

    7. You have free access to this content
      A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry (pages 3945–3953)

      Nan Li, Li Xu, Hui Zhao, Adel K. El-Naggar and Erich M. Sturgis

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26740

      The demographics and clinical features of adenoid cystic carcinoma differ by disease site. Anatomic site may be an important predictor of survival for patients who present with localized disease but is less important for patients who present with regional disease.

    8. Hematologic Malignancies
      You have free access to this content
      Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas : Phase 2 study of the Italian Lymphoma Foundation (pages 3954–3961)

      Andrea Ferrario, Alessandro Pulsoni, Barbara Olivero, Giuseppe Rossi, Umberto Vitolo, Alessandra Tedeschi, Francesco Merli, Luigi Rigacci, Caterina Stelitano, Maria Goldaniga, Donato Mannina, Pellegrino Musto, Francesca Rossi, Enrica Gamba and Luca Baldini

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26708

      Indolent nonfollicular non-Hodgkin B-cell lymphomas are clonal mature B-cell proliferations for which treatment has not been defined to date. The combination of rituximab, fludarabine, and cyclophosphamide as induction immunochemotherapy followed by a short maintenance phase with rituximab is a highly effective regimen with acceptable toxicity in this subset of lymphomas.

    9. You have free access to this content
      Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis (pages 3962–3967)

      Amal Abdulwahab, Jenna Sykes, Suzanne Kamel-Reid, Hong Chang and Joseph M. Brandwein

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26735

      Seven percent of adult acute lymphoblastic leukemia cases have received prior chemotherapy and/or radiotherapy. Nearly 80% have high-risk features, most commonly MLL rearrangements, and overall prognosis is poor.

    10. You have free access to this content
      A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF) (pages 3968–3976)

      Nelli Bejanyan, Ramon V. Tiu, Azra Raza, Ania Jankowska, Matt Kalaycio, Anjali Advani, Josephine Chan, Yogen Saunthararajah, Lindsey Mooney, Jaroslaw P. Maciejewski and Mikkael A. Sekeres

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26741

      The thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) regimen yields clinical responses in patients with primary myelofibrosis and myelodysplastic/myeloproliferative neoplasms. It is reasonable to incorporate multiple novel agents in these rare diseases.

    11. You have free access to this content
      Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma (pages 3977–3983)

      Stefan K. Barta, Jeannette Y. Lee, Lawrence D. Kaplan, Ariela Noy and Joseph A. Sparano

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26723

      Clinical outcomes improve for patients with human immunodeficiency virus-associated lymphoma who receive concurrent rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin compared with patients who receive rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone when the analyses are adjusted for other covariates in a pooled analysis that includes 2 consecutive clinical trials. In addition, treatment-associated deaths occur significantly more often in patients who have baseline CD4 counts <50/μL irrespective of therapy.

    12. Hepatobiliary Disease
      You have free access to this content
      A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma (pages 3984–3992)

      Stephen L. Chan, Frankie K. F. Mo, Cesar S. C. Wong, Charles M. L. Chan, Linda K. S. Leung, Edwin P. Hui, Brigette B. Ma, Anthony T. C. Chan, Tony S. K. Mok and Winnie Yeo

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26726

      In this study, the serum interleukin 10 (IL-10) level is identified as an independent prognostic factor for unresectable hepatocellular carcinoma that is related chiefly to hepatic injury caused by cirrhotic processes. The IL-10 level offers additional prognostic value to the existing tumor staging systems.

    13. Lung Disease
      You have free access to this content
      Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors (pages 3993–4003)

      Woo-Young Kim, Ludmila Prudkin, Lei Feng, Edward S. Kim, Bryan Hennessy, Ju-Seog Lee, J. Jack Lee, Bonnie Glisson, Scott M. Lippman, Ignacio I. Wistuba, Waun Ki Hong and Ho-Young Lee

      Article first published online: 22 FEB 2012 | DOI: 10.1002/cncr.26656

      This study provides evidence for the first time that the mutation status of both epidermal growth factor receptor (EGFR) and K-Ras could be a predictive marker for response to insulinlike growth factor 1 receptor (IGF-1R) tyrosine kinase inhibitors (TKIs). Also, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase antagonism can abrogate primary resistance of nonsmall cell lung cancer to IGF-1R TKIs.

      Corrected by:

      Erratum: Erratum

      Vol. 118, Issue 24, 6301, Article first published online: 17 MAY 2012

    14. Melanoma
      You have free access to this content
      Examining the pathways linking lower socioeconomic status and advanced melanoma (pages 4004–4013)

      Ricardo A. Pollitt, Susan M. Swetter, Timothy M. Johnson, Pratima Patil and Alan C. Geller

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26706

      The authors examined several potential pathways that may play a role in the previously described socioeconomic disparity in melanoma stage at diagnosis and survival. Less educated melanoma patients have little awareness of the risks of melanoma and less basic knowledge about melanoma detection, and they receive less physician communication about melanoma risk factors and screening and fewer physician skin examinations than more educated patients.

    15. You have free access to this content
      NRAS mutation status is an independent prognostic factor in metastatic melanoma (pages 4014–4023)

      John A. Jakob, Roland L. Bassett Jr., Chaan S. Ng, Jonathan L. Curry, Richard W. Joseph, Gladys C. Alvarado, Michelle L. Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim, Alexander J. Lazar, Patrick Hwu and Michael A. Davies

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26724

      Patients who have metastatic melanoma with mutations of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) or neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) genes are more likely than those with the wild-type of both genes to have central nervous system involvement at the diagnosis of distant metastases. NRAS mutation status is an independent predictor of shorter survival after the diagnosis of stage IV melanoma.

    16. Discipline

      Disparities Research
      You have free access to this content
      Associations among physical activity, body mass index, and health-related quality of life by race/ethnicity in a diverse sample of breast cancer survivors (pages 4024–4031)

      Raheem J. Paxton, Karon L. Phillips, Lovell A. Jones, Shine Chang, Wendell C. Taylor, Kerry S. Courneya and John P. Pierce

      Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.27389

      Breast cancer survivors from minority populations have lower levels of physical activity and higher rates of obesity that are generally associated with poorer health-related quality of life, possibly explaining their higher recurrence risk. Culturally sensitive physical activity and weight loss interventions might lower this risk.

    17. You have free access to this content
      Cancer mortality-to-incidence ratios in Georgia : Describing racial cancer disparities and potential geographic determinants (pages 4032–4045)

      Sara E. Wagner, Deborah M. Hurley, James R. Hébert, Chrissy McNamara, A. Rana Bayakly and John E. Vena

      Article first published online: 31 JAN 2012 | DOI: 10.1002/cncr.26728

      More fatal cancers, particularly prostate, cervical, and oral cancer in men, are detected among blacks, especially in central Georgia, where health behavior and social/economic factors are worse. Mortality-to-incidence ratios are an efficient indicator of survival and provide insight into racial cancer disparities.

    18. Epidemiology
      You have free access to this content
      Statin use and fatal prostate cancer : A matched case-control study (pages 4046–4052)

      Stephen W. Marcella, Alice David, Pamela A. Ohman-Strickland, Jeffery Carson and George G. Rhoads

      Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26720

      This population-based, case-control study investigates the association of statin use with prostate cancer mortality. The results reveal that exposure to statin medication is associated with an approximately 50% decrease in prostate cancer mortality.

    19. Radiation Oncology
      You have free access to this content
      Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy (pages 4053–4062)

      Gaetano Zafarana, Adrian S. Ishkanian, Chad A. Malloff, Jennifer A. Locke, Jenna Sykes, John Thoms, Wan L. Lam, Jeremy A. Squire, Maisa Yoshimoto, Varune Rohan Ramnarine, Alice Meng, Omar Ahmed, Igor Jurisca, Michael Milosevic, Melania Pintilie, Theo van der Kwast and Robert G. Bristow

      Article first published online: 26 JAN 2012 | DOI: 10.1002/cncr.26729

      Array-based comparative genomic hybridization analysis of frozen, pretreatment biopsies from 126 patients with intermediate-risk prostate cancer demonstrates that copy number alterations in c-MYC and PTEN genes are prognostic for relapse following modern era image-guided radiotherapy.

    20. Translational Research
      You have free access to this content
      Identification of novel germline polymorphisms governing capecitabine sensitivity (pages 4063–4073)

      Peter H. O'Donnell, Amy L. Stark, Eric R. Gamazon, Heather E. Wheeler, Bridget E. McIlwee, Lidija Gorsic, Hae Kyung Im, R. Stephanie Huang, Nancy J. Cox and M. Eileen Dolan

      Article first published online: 3 JAN 2012 | DOI: 10.1002/cncr.26737

      To guide the selection of patients potentially at greatest benefit of experiencing antitumor efficacy from capecitabine, or, alternatively, of developing capecitabine toxicities, the authors identify several novel germline predictors of capecitabine sensitivity using a genome-wide and meta-analysis approach.

    21. You have free access to this content
      The role of DNA methyltransferase 3b in esophageal squamous cell carcinoma (pages 4074–4089)

      Miao-Fen Chen, Ming-Shian Lu, Paul-Yang Lin, Ping-Tsung Chen, Wen-Cheng Chen and Kuan-Der Lee

      Article first published online: 27 DEC 2011 | DOI: 10.1002/cncr.26736

      The incidence of nuclear DNA methyltransferase 3b (DNMT3b) immunoreactivity in specimens from patients with esophageal cancer is significantly higher than that in nonmalignant epithelium, and this incidence is linked positively to developing distant metastasis and to a poor prognosis. Targeting DNMT3b may be a promising strategy for treating esophageal cancer, as evidenced by inhibited aggressive tumor behavior and treatment resistance.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Surgical management of children with locally advanced hepatoblastoma (pages 4090–4091)

      Rebecka L. Meyers, Gregory M. Tiao, Stephen P. Dunn, Eugene D. McGahren III, Max R. Langham Jr and On behalf of the Central Surgical Review Committee, Children's Oncology Group AHEP-0731, Treatment of Children with All Stages Hepatoblastoma

      Article first published online: 3 JUL 2012 | DOI: 10.1002/cncr.26715

    2. You have free access to this content
      Comments on surgical treatment of locally advanced hepatoblastoma (pages 4092–4093)

      On behalf of the International Childhood Liver Tumors Strategy Group (SIOPEL):, Piotr Czauderna, Jean-Bernard Otte and Derek J. Roebuck

      Article first published online: 3 JUL 2012 | DOI: 10.1002/cncr.26714

    3. You have free access to this content

SEARCH

SEARCH BY CITATION